Relypsa (RLYP) in Focus: Stock Adds 12.4% in Session - Tale of the Tape


Relypsa, Inc . ( RLYP ) was a big mover last session with shares rising over 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company as the stock has lost over 11% in the last five trading sessions.

This pharmaceutical company has seen three negative estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved lower over the same period. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's rally can last.

Relypsa currently has a Zacks Rank #4 (Sell) while its  Earnings ESP  is 0.00%.

Some better-ranked generic Med-Drug stocks are Dr. Reddy's Laboratories Ltd. ( RDY ), Mallinckrodt plc ( MNK ) and Actavis plc ( ACT ). While RDY and MNK sport a Zacks Rank #1 (Strong Buy), ACT holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

ACTAVIS PLC (ACT): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

DOCTOR REDDYS (RDY): Free Stock Analysis Report

RELYPSA INC (RLYP): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Investing Ideas , Stocks

Referenced Stocks: ACT , MNK , RDY , RLYP

More from

Related Videos



Most Active by Volume

  • $16.72 ▲ 1.03%
  • $6.81 ▲ 8.27%
  • $33.27 ▼ 1.87%
  • $15.26 ▼ 0.65%
  • $129.96 ▼ 0.44%
  • $8.92 ▲ 6.57%
  • $5.16 ▲ 1.57%
  • $11.05 ▲ 3.37%
As of 6/2/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by